Earnings Scheduled For March 9, 2023
Companies Reporting Before The Bell
• Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.
Acorda Therapeutics Q4 EPS $(0.57) Up From $(1.73) YoY, Sales $31.47M Down From $36.97M YoY
Acorda Therapeutics (NASDAQ:ACOR) reported quarterly losses of $(0.57) per share. This is a 67.05 percent increase over losses of $(1.73) per share from the same period last year. The company reported $31.47 million in
Acorda Therapeutics Announces New Agreement With Catalent For Long-Term Global Supply Of INBRIJA
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that on December 31, 2022 it entered into a new long-term global supply agreement with Catalent for the manufacture of INBRIJA (levodopa inhalation powder) at its
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
Key Assumptions Underlying Business Plan and Guidance Remain Unchanged
INBRIJA will continue to grow in the U.S.
INBRIJA will expand into additional ex-U.S. markets
AMPYRA will continue to lose market
Acorda Therapeutics Receives Nasdaq Listing Determination Letter, Plans To Request Hearing
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that, due to the Company's common stock not having regained compliance
Acorda Therapeutics Announces Passage Of ~2.5:1 Reverse Stock Split Proposal At Special Meeting of Stockholders
"We are grateful to our shareholders who supported this proposal at a ratio of almost two and a half to one. Authorizing our board to implement a reverse stock split is an important tool, if needed, to ensure that
How Is The Market Feeling About Acorda Therapeutics?
Acorda Therapeutics's (NASDAQ:ACOR) short percent of float has risen 230.3% since its last report. The company recently reported that it has 792 thousand shares sold short, which is 3.27% of all regular shares that are available for trading.
Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday
Gainers
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product candidates.
